Veterinary Medicines

Gallifen 200 mg/ml suspension for use in drinking water for chickens and pheasants

Authorised
  • Fenbendazole
Download as PDF

Product identification

Medicine name:
Gallifen 200 mg/ml suspension for use in drinking water for chickens and pheasants
Gallifen 200 mg/ml Suspensie voor gebruik in drinkwater
Gallifen 200 mg/ml Suspension pour administration dans l'eau de boisson
Gallifen 200 mg/ml Suspension zum Eingeben über das Trinkwasser
Active substance:
  • Fenbendazole
Target species:
  • Chicken
  • Pheasant
Route of administration:
  • In drinking water use

Product details

Active substance and strength:
  • Fenbendazole
    200.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for use in drinking water
Withdrawal period by route of administration:
  • In drinking water use
    • Chicken
      • Eggs
        0
        day
      • Meat and offal
        8
        day
      • Meat and offal
        6
        day
    • Pheasant
      • Eggs
        0
        day
      • Meat and offal
        6
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC13
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • White rectangular HDPE bottle of 1 litre with vertically see-through bar with an LDPE insert closed with white PP tamper- evident screw cap with a LDPE sealing disk.
  • White HDPE canisters with white HDPE ribbed tamper-evident screw cap of 5 litres.
  • White HDPE canisters with white HDPE ribbed tamper-evident screw cap of 2.5 litres.
  • White cylindrical High Density Polyethylene (HDPE) bottle with white polypropylene (PP) screw tamper-evident closure of 1 litre.
  • White cylindrical High Density Polyethylene (HDPE) bottle with white polypropylene (PP) screw tamper-evident closure of 125 ml.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • HuVepharma
Marketing authorisation date:
Manufacturing sites for batch release:
  • Biovet J.S.C.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0579/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download
German (PDF)
Published on: 22/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."